AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 Years

AbCellera Biologics Inc. (NASDAQ:ABCL) ranks among the stocks that could 10x over the next 5 years. On March 17, AbCellera Biologics Inc. (NASDAQ:ABCL) outlined its vision at the KeyBanc Capital Markets Healthcare Forum 2026, emphasizing its transition to a mid- to late-stage biotech with significant drug discovery capabilities.

The company boasted a strong financial position, with around $700 million in cash and a three-year runway supported by government funding. Its annual cash burn of $120 to $130 million also funds early-stage development across many programs.

The AbCellera Biologics Inc. (NASDAQ:ABCL) pipeline is also in focus, which includes ABCL635, currently in Phase 2 trials for the non-hormonal treatment of hot flashes, with potential development into cancer-related applications. ABCL575 is in Phase 1 testing for immunological diseases, with plans for further collaborations.

Meanwhile, on February 24, AbCellera Biologics Inc. (NASDAQ:ABCL) announced earnings per share of -0.03, compared to an expected loss of $0.18, reflecting an 83.33% earnings outperformance.

Its revenue climbed by $39.80 million over the previous year. The fourth-quarter results came after a difficult third quarter in 2025, when ABCL missed earnings per share projections by $0.02.

AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody-based medicines for indications with unmet medical needs in the US.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. 

Disclosure: None. Follow Insider Monkey on Google News.